Skip to main content
Blood Advances logoLink to Blood Advances
. 2023 Jan 5;7(1):159–161. doi: 10.1182/bloodadvances.2022007909

Bruscaggin A, Terzi di Bergamo L, Spina V, et al. Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab. Blood Adv. 2021;5(22):4674-4685.

PMCID: PMC9829521  PMID: 36598793

Page 4679: In Figure 3E-H, the greater-than and less-than signs for the cutoff of 1900 hGE/mL were reversed. Red should correspond to <1900 hGE/mL, not >1900 hGE/mL; blue should correspond to >1900 hGE/mL, not <1900 hGE/mL. In the legend, red should correspond to <1900 hGE/mL, not >1900 hGE/mL; blue should correspond to >1900 hGE/mL, not ≤1900 hGE/mL. The corrected Figure 3 is shown below.

Figure 3.

Figure 3

Kaplan-Meier curves of PFS stratified according to the pretreatment TP53 status and pretreatment ctDNA load. All cohorts stratified by TP53 mutation status (A), relapsed FL stratified by TP53 mutation status (B), relapsed DLBCL stratified by TP53 mutation status (C), and RS stratified by TP53 mutation status (D). Red: mutated (MUT); blue: wild-type (WT). All cohorts stratified by ctDNA load measured in haploid genomic equivalents per mL of plasma (E), relapsed FL stratified by ctDNA load (F), relapsed DLBCL stratified by ctDNA load (G), and RS stratified by ctDNA load (H). Red: ctDNA load <1900 hGE/mL of plasma; blue: ctDNA load >1900 hGE/mL of plasma.

The publisher apologizes for the errors.


Articles from Blood Advances are provided here courtesy of The American Society of Hematology

RESOURCES